New federal guidance on medical cannabis is drawing attention to a growing gap in Canadian health care: patients are increasingly using cannabis to manage symptoms, but often without consistent clinical education, dosage support or drug interaction screening.
In January 2026, Health Canada published Information on the Medical Uses of Cannabis, a guidance document for consumers that includes contraindications, possible drug interactions, dosing and titration principles, and potential adverse effects.
Legal cannabis products produced and sold in Canada are not licensed to treat specific diseases or symptoms and have not been reviewed to determine whether they are safe or effective for those purposes.
“This is top-to-bottom healthcare,” said Ajay Chahal, PharmD, co-founder of Apothecare. “Health Canada has done the work to put clear guidelines to Canadians, but it’s absurd that patients are still forced to be their own physician educators. We’ve created a reality where patients are forced to turn to budtenders for pseudo-clinical advice, product recommendations for sleep, pain, anxiety or cancer-related symptoms based on anecdotes that work for someone I know. That’s not informed care, it’s a symptom of a system that has failed.”
Health Canada says that the use of cannabis carries health risks that are not yet fully understood and advises Canadians to consult their health care provider before using cannabis for medical purposes.
“That warning should set the system in motion,” said Anushya Vijayaraghevan, PharmD, co-founder of Apothecare. “Patients should not gamble with their health to relieve symptoms. If a patient is taking antidepressants, blood thinners, seizure medications, or has mental health vulnerabilities, the stakes are real. However, patients are often left to make product decisions and trial-and-error dosing with little guidance from the clinical system they are supposed to protect.”
In response to Health Canada’s guidelines, Apothecare is calling for four immediate actions to close the cannabis education gap in Canadian healthcare. First, medical cannabis education should be integrated into the core training of physicians, pharmacists, nurses, and allied health providers, with standardized learning outcomes that address dosage, contraindications, impairment, and drug interactions. Cannabis is already being used by patients across the country, and clinicians need a shared baseline of knowledge to manage it safely and consistently.
Second, clinical cannabis counseling should be established as a standard for patient safety. Canadians deserve access to evidence-based guidance that is medically responsible, consistent across care settings and independent of retail environments. Without clinical advice, patients are often left to navigate complex decisions on their own, increasing the risk of misuse, adverse effects, or missed interactions with other therapies.
Third, continuing education requirements through professional organizations need to be modernized so that clinicians can keep pace as cannabis use becomes more common for symptom management. Continuing education allows health care providers to confidently counsel patients, analyze risk factors, and adapt care as evidence evolves, rather than relying on outdated information or comfort levels.
Finally, cannabis should be treated like other pharmacologically active therapies in routine care. This means standardizing patient disclosure, documenting use in medical records, and supporting appropriate follow-up and monitoring. By moving away from a trial-and-error approach, it will help integrate cannabis into standard care practices and improve patient safety and outcomes.
“This is not about being for or against cannabis,” Vijayaragheva said. “It’s about accountability. The system can’t ignore something this widespread and then act surprised when patients are confused, underinformed or harmed. We have the knowledge and the clinical space to do better, but it needs to be prioritized.”
“This should not be controversial,” Chahal said. “If millions of Canadians use cannabis for medical purposes, then millions of Canadians deserve professional-level education, consistent clinical supervision and clear safety standards.”
For more information:
Apothecare
https://apothecare.ca/